MRNA Jun 2026 95.000 put
- Reuters
GlaxoSmithKline sues Moderna for US patent infringement over COVID vaccines
(Reuters) -British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing its American rival of violating GSK's patent rights in messenger RNA (mRNA) technology with its blockbuster COVID-19 vaccine Spikevax. According to the two lawsuits, Moderna's lipid nanoparticles for transporting fragile mRNA into the human body infringe several GSK patents covering similar innovations. GSK filed a related lawsuit against Pfizer and BioNTech in the same court in April over their COVID-19 vaccine.
- Zacks
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
- Zacks
Moderna (MRNA) Stock Sinks As Market Gains: Here's Why
The latest trading day saw Moderna (MRNA) settling at $57.73, representing a -0.96% change from its previous close.
